Sito in Italia dove è possibile acquistare la consegna acquisto Viagra a buon mercato e di alta qualità in ogni parte del mondo.

C:\program files\wercs50\docs\wercs.ps

MATERIAL SAFETY DATA SHEET
Personal Protective Equipment
See Section 8.
1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION
Product code:

Product Name:
Chemical Name:
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, monohydrochloride hydrate Synonyms:
3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, monohydrochloride, monohydrateCiprofloxacin hydrochloride monohydrateCiprofloxacin hydrochloride hydrate Recommended use:
Formula:
Supplier:
Spectrum Chemicals and Laboratory Products, Inc.
14422 South San Pedro St.
Gardena, CA 90248(310) 516-8000 Emergency Telephone Number:
Contact Person:
Contact Person:
2. HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
May cause skin and eye irritation. May cause irritation of respiratory tract.
Physical state:
Appearance:
OSHA Regulatory Status
This material is not considered hazardous by the OSHA Hazard CommunicationStandard (29 1910.1200) Product code: C2213
Product name: CIPROFLOXACIN
2. HAZARDS IDENTIFICATION
POTENTIAL HEALTH EFFECTS
Principal Routes of Exposure:
Ingestion. Inhalation.
Acute Potential Health Effects:
Skin Contact:
May cause skin irritation.
Eye Contact:
May cause eye irritation.
Inhalation:
May cause irritation of respiratory tract.
Ingestion:
Ingestion may cause vomiting and nausea. May cause abdominal discomfort. May cause diarrhea. May cause
constipation. It may affect the kidneys. May affect the liver. May cause central nervous system effects. May affect the
blood. May affect the cardiovascular system.
Chronic Potential Health Effects:
Target Organs:
Kidneys. Liver. Central nervous system. Musculoskeletal system (joints, tendons).
Carcinogen Status:
Mutagenic Effects:
May affect genetic materialExperiments with bacteria have shown mutagenic effectsAnimal experiments showed mutagenic effectsExperiments with human lymphocytes have shown mutagenic effects Teratogenic Effects:
Aggravated Medical Conditions: Liver disease. Kidney disease. Heart condition. Seizures. Hypersensitivity to
material. Hypersensitivity to fluoroquinolones. Flare-up of gout. Worsening ofmyasthenia gravis.
See Section 11 for additional Toxicological Information
POTENTIAL ENVIRONMENTAL EFFECTS
3. COMPOSITION/INFORMATION ON INGREDIENTS
Components
4. FIRST AID MEASURES
General Advice:
Poison information centres in each State capital city can provide additionalassistance for scheduled poisons (13 1126) Product code: C2213
Product name: CIPROFLOXACIN
Skin Contact:
Wash off immediately with soap and plenty of water removing all contaminatedclothes and shoes. Get medical attention if irritation develops.
Eye Contact:
Flush eye with water for 15 minutes. Get medical attention if irritation occurs. Ifsymptoms persist, call a physician.
Inhalation:
Move to fresh air. If breathing is difficult, give oxygen. In case of shortness of breath,give oxygen. Get medical attention.
Ingestion:
Do not induce vomiting without medical advice. Never give anything by mouth to anunconscious person. Consult a physician if necessary.
Notes to Physician:
5. FIRE-FIGHTING MEASURES
Flammable Properties
Flashpoint (°C/°F):
Tested according to:
Not applicable
Lower Explosion Limit (%):
Upper Explosion Limit (%):
Autoignition Temperature (°C/°F): No information available
Suitable Extinguishing Media:
Carbon dioxide (CO2). Dry chemical. Water spray mist orfoam.
Unsuitable Extinguishing Media:
Hazardous Combustion Products:
Specific hazards:
May be combustible at high temperatures.
Special Protective Equipment for Firefighters:
As in any fire, wear self-contained breathing apparatuspressure-demand, MSHA/NIOSH (approved or equivalent)and full protective gear Specific Methods:
6. ACCIDENTAL RELEASE MEASURES
Personal Precautions:
Ensure adequate ventilation. Use personal protective equipment. Avoid contact with skin, eyes and clothing. Avoid dust
formation. Remove all sources of ignition.
Environmental Precautions:
No information available.
Methods for Cleaning Up:
Sweep up and shovel into suitable containers for disposal. Avoid dust formation. Clean contaminated surface thoroughly.
Product code: C2213
Product name: CIPROFLOXACIN
7. HANDLING AND STORAGE
Handling
Technical Measures/Precautions:
Provide sufficient air exchange and/or exhaust in work rooms. Avoid dust formation. All equipment used when
handling the product must be grounded. Keep away from incompatible materials.
Safe Handling Advice:
Wear personal protective equipment. Avoid contact with skin, eyes and clothing. Avoid dust formation. Do not
ingest. Do not breathe vapours/dust. Keep away from heat and sources of ignition. Handle in accordance with good
industrial hygiene and safety practice.
Technical Measures/Storage Conditions:
Keep container tightly closed in a dry and well-ventilated place. Store at room temperature in the original container.
Sensitive to light. Store in light-resistant containers. Store away from incompatible materials.
Incompatible Products:
Oxidizing agents. Iron.
8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Engineering measures to reduce exposure:
Ensure adequate ventilation. Use process enclosures, localexhaust ventilation, or other engineering controls to keepairborne levels below recommended exposure limits. If useroperations generate dust, fume or mist, use ventilation tokeep exposure to airborne contaminants below the exposurelimit.
Personal Protective Equipment
Eye protection:
Safety glasses. Safety glasses with side-shields.
Skin and body protection:
Long sleeved clothing. Chemical resistant apron. Gloves.
Respiratory protection:
Hygiene measures:
Avoid contact with skin, eyes and clothing. Wash hands before breaks andimmediately after handling the product. When using, do not eat, drink or smoke.
National occupational exposure limits
United States
U.S Occupational Exposure Limits:
Not determined
Canada
Canada Occupational Exposure Limits:
Not determined
Australia and Mexico
Occupational Exposure Limits for Australia and Mexico:
Not determined
9. PHYSICAL AND CHEMICAL PROPERTIES
Product code: C2213
Product name: CIPROFLOXACIN
9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state:
Appearance:
Molecular/Formula weight:
Flash point (°C):
Lower Explosion Limit (%):
Upper Explosion Limit (%):
Autoignition Temperature (°C/°F):
Boiling point/range(°C/°F):
Melting point/range(°C/°F):
Decomposition temperature(°C/°F):
Specific gravity:
Density (g/cm3):
Bulk density:
Vapor pressure @ 20°C (kPa):
Vapor density:
Evaporation rate:
VOC content (g/L):
Odor threshold (ppm):
Partition coefficient
Miscibility:
(n-octanol/water):
Solubility:
Sparingly soluble in water
Very slightly soluble in Ethanol
Slightly soluble in glacial Acetic acid
Slightly soluble in Methanol
Practically insoluble in Acetone
Practically insoluble in Acetonitrile
Practically insoluble in
Dichloromethane
Practically insoluble in Ethyl Acetate
Practically insoluble in Hexane
10. STABILITY AND REACTIVITY
Stability:
Conditions to avoid:
Heat. Avoid dust formation. Dust may form explosive mixture in air. Fine dustdispersed in air in sufficient concentrations, and in the presence of an ignition sourceis a potential dust explosion hazard. Incompatible materials.
Materials to avoid:
Hazardous decomposition
products:
Possibility of Hazardous
Reactions:
Polymerization:
Corrosivity:
Special Remarks on Corrosivity: No information available
Product code: C2213
Product name: CIPROFLOXACIN
11. TOXICOLOGICAL INFORMATION
Acute Toxicity
Component Information
Ciprofloxacin Hydrochloride - 86393-32-0 LD50/oral/rat = No information available
LD50/oral/mouse = No information available
LD50/dermal/rabbit = No information available
LD50/dermal/rat = No information available
LC50/inhalation/rat = No information available
LC50/inhalation/mouse = No infomaton available
Other LD50 information = No information available
Product Information
LC50/inhalation/rat = No information available
LC50/Inhalation/mouse = No information available
LD50/dermal/rabbit = No information available
LD50/dermal/rat = No information available
LD50/oral/rat = No information available
LD50/oral/mouse = No information available
Local Effects
Skin irritation:
Eye irritation:
Contact with eyes may cause irritation. May cause burning, itching, tearing,conjunctival hyperemia, lid edema, keratitis, decreased vision, photophobia.
Inhalation:
May cause irritation of respiratory tract.
Ingestion:
Ingestion may cause nausea, vomiting, diarrhea. May cause constipation. May causeupset stomach. May cause abdominal pain. May cause heartburn. May causedyspepsia. May cause dysphagia (difficulty swallowing; pain while swallowing). Maycause flatulence. May cause dry mouth. May cause pain in the mouth with redness,blistering, white patches or sores. May affect behavior/central nervous system(somnolence, tremor, hallucinations). May affect the cardiovascular system (pulserate, hypotension, hypertension, palpitations, atrial flutter, angina pectoris, syncope,vasculitis). May affect the blood (changes in white blood cell count, hemolyticanemia, methemoglobinemia). It may affect the spleen. It may affect the pancreas(pancreatitis). May cause hyperglycemia. May cause hyperkalemia.
Sensitization:
Chronic Toxicity
Product code: C2213
Product name: CIPROFLOXACIN
Chronic Toxicity
Prolonged or repeated ingestion may affect behavior/central nervous system(headache, somnolence, weakness, lethargy, fatigue, drowsiness, hallucinations,agitation, restlessness, irritability, confusion, tremor, delirium, nightmares, insomnialightheadness, ataxia, seizures, dizziness, ). Prolonged or repeated ingestion mayaffect the musculoskeletal system (joints, tendons) and cause tendonitis, tendonrupture, myalgia, myoclonus, joint pain or stiffness, back or neck pain. Prolonged orrepeated ingestion may affect the liver (jaundice, liver function tests impaired, hepaticnecrosis), and urinary system/kidneys (nephritis, hematuria, cylindruria, renal failure,urinary retention, polyuria, urethral bleeding, renal calculi, interstitial nephritis).
Prolonged or repeated ingestion may affect the blood (changes in cell count,eosinophilia, agranulocytosis, leukopenia, leukocytosis, pancytopenia). Prolonged orrepeated ingestion may cause cutaneous candidiasis, photosensitivity,hyperpigmentation, and hypersensitivity or anaphylactic reactions such dermatitis,urticaria, flushing, rash, erythema nodosum, swellling of the lips, neck, face,conjunctivae, hands, angioedema, difficulty breathing, shortness of breath, Stevens-Johnson syndrome.
Carcinogenic effects:
Mutagenic Effects:
May affect genetic materialExperiments with bacteria have shown mutagenic effectsAnimal experiments showed mutagenic effectsExperiments with human lymphocytes have shown mutagenic effects Reproductive Effects:
Teratogenic Effects:
Target Organs:
Kidneys. Liver. Central nervous system. Musculoskeletal system (joints, tendons).
12. ECOLOGICAL INFORMATION
ECOTOXICITY
Toxicity to terrestrial and aquatic plants and animals:
Ecotoxicity effects:
Aquatic toxicity:
Mobility:
Persistence and degradability:
Bioaccumulative potential:
13. DISPOSAL CONSIDERATIONS
Waste from residues / unused products:
Waste must be disposed of in accordance with Federal, State and Local regulation.
Contaminated packaging:
Empty containers should be taken for local recycling, recovery or waste disposal
Components
RCRA - F Series Wastes RCRA - K Series Wastes RCRA - P Series Wastes
RCRA - U Series Wastes
Product code: C2213
Product name: CIPROFLOXACIN
14. TRANSPORT INFORMATION
Proper Shipping Name:
Hazard Class:
Packing Group:
Subsidiary Risk:
Marine Pollutant
DOT RQ (lbs):
TDG (Canada)
Proper Shipping Name:
Hazard Class:
Packing Group:
Subsidiary Risk:
Description:
Proper Shipping Name:
Hazard Class:
Packing Group:
Subsidiary Risk:
Classification Code:
Description:
CEFIC Tremcard No:
IMO / IMDG
Proper Shipping Name:
Hazard Class:
Subsidiary Risk:
Packing Group:
Description:
IMDG Page:
Marine Pollutant
Maximum Quantity:
Proper Shipping Name:
Hazard Class:
Packing Group:
Subsidiary Risk:
Classification Code:
Description:
Hazard Class:
Proper Shipping Name:
Packing Group:
Subsidiary Risk:
Product code: C2213
Product name: CIPROFLOXACIN
Description:
Proper Shipping Name:
Hazard Class:
Packing Group:
Subsidiary Risk:
Description:
15. REGULATORY INFORMATION
International Inventories
Components
U.S. TSCA
Philippines
Australia
EINECS-No.
U.S. Regulations
California Prop. 65: Safe Drinking Water and Toxic Enforcment Act of 1986.
Chemicals Known to the State of California to Cause Cancer:
This product does not contain a chemical requiring a warning under California Prop. 65. (See table below)
Chemicals Known to the State of California to Cause Reproductive Toxicity:
This product does not contain a chemical requiring a warning under California Prop. 65. (See table below)
Components
Carcinogen
Developmental Toxicity
Male Reproductive
Female Reproductive
Toxicity
Toxicity:
CERCLA/SARA
Components
CERCLA - Hazardous Section 302 Extremely Section 302 Extremely
Section 313 -
Section 313 - Reporting
Substances and their
Hazardous
Hazardous
Chemical Category
de minimis
Reportable Quantities Substances and TPQs Substances and RQs
U.S. TSCA
Components
TSCA Section 5(a)2 - Chemicals With Significant
TSCA 8(d) -Health and Safety Reporting
New Use Rules (SNURS)
WHMIS hazard class:
Non-controlled
Canada Controlled Products Regulation:
This product has been classified according to the hazard criteria of the CPR (Controlled Products Regulation) and the MSDS contains
all of the information required by the CPR.
Inventory
Product code: C2213
Product name: CIPROFLOXACIN
Components
Canada (DSL)
Canada (NDSL)
EU Classification
R -phrase(s)
not determined
S -phrase(s)
none
The product is classified in accordance with Annex VI to Directive 67/548/EEC
Indication of danger:
Not dangerous
16. OTHER INFORMATION
The MSDS format complies with ANSI Z400.1-2004 standards.
Preparation Date
Reason for revision:
Prepared by:
Literature reference:
All chemicals may pose unknown hazards and should be used with caution. This Material Safety Data Sheet (MSDS)applies only to the material as packaged. If this product is combined with other materials, deteriorates, or becomescontaminated, it may pose hazards not mentioned in this MSDS. The physical properties reported in this MSDS areobtained from the literature and do not constitute product specifications. Information contained herein does not constitutea warranty, whether expressed or implied, as to the safety, merchantability or fitness of the goods for a particular purpose.
Spectrum Chemicals & Laboratory Products, Inc. assumes no responsibility for results obtained or for incidental orconsequential damages, including lost profits, arising from the use of these data. No warranty against infringement of anypatent, copyright or trademark is made or implied. It shall be the user's responsibility to develop proper methods ofhandling and personal protection based on the actual conditions of use. While this MSDS is based on technical datajudged to be reliable, Spectrum assumes no responsibility for the completeness or accuracy of the information containedherein.
Product code: C2213
Product name: CIPROFLOXACIN

Source: http://phm.utoronto.ca/~ddubins/MSDS/Ciprofloxacin_MSDS.pdf

Chlorophyll – zehnmal wirksamer gegen krebs als chemotherapie

Chlorophyll: Zehnmal wirksamer gegen Krebs als Chemotherapie Warum Chlorophyll und damit grüne Pflanzen Krebs heilen können. Neueste Forschungen des Linus-Pauling-Insituts der Oregon State University lassen vermuten, dass natürliche Substanzen wie etwa der grüne Pflanzenfarbstoff Chlorophyll oder Selen aus Knoblauch und der Paranuss im Kampf gegen Krebserkrankungen eine möglicherweis

Microsoft word - 2012 eana annual report_121213.doc

2012 EANA Annual Report 1. What is EANA? EANA, the European Astrobiology Network Association, was founded in 2001 as a scientific non-profit organisation with the purpose to bring together European researchers interested in that new field of astrobiology, to foster their cooperation, to attract students and young scientists and to popularize astrobiology. EANA is registered at the Prefec

Copyright © 2010-2014 Medicament Inoculation Pdf